Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation.
Beta-blocker
Exercise capacity
Hypertrophic cardiomyopathy
LVOT obstruction
Quality of life
Septal reduction therapy
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
18
10
2023
revised:
13
11
2023
accepted:
25
11
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
epublish
Résumé
The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
Sections du résumé
Background
UNASSIGNED
The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA.
Methods
UNASSIGNED
This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO
Results
UNASSIGNED
No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO
Conclusions
UNASSIGNED
In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
Identifiants
pubmed: 38126007
doi: 10.1016/j.ijcha.2023.101317
pii: S2352-9067(23)00148-3
pmc: PMC10731216
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101317Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.